

CV Form

Name(中/英文)	曾湘文/Hsiang-Wen Tseng	
Affiliation(s)(中/英文)	進階生物科技股份有限公司/ Level Biotechnology Inc.	
Current Position Title	副總經理/ Vice President	
E-mail/Phone Number	tsenghw@mail.level.com.tw ; tsenghw@gmail.com 0928814647	
Personal Website	https://orcid.org/0000-0001-8459-6347	

個人簡歷 (No more than an A4 size paper)

Education/Training:

- Ph.D.: Institute of Pharmacology, National Yang Ming Chiao Tung University, Taiwan, 2001 – 2006
- Master: Institute of Pharmacology, National Yang Ming Chiao Tung University, Taiwan, 1999 – 2001
- B.S.: Bachelor of Pharmacy, School of Pharmacy, Taipei Medical University, Taiwan, 1993 – 1997

Professional and Research Experience:

Vice President, Preclinical Testing Center, Level Biotechnology Inc., Taiwan

Jan. 2022 – Present

Assistant Vice President, Preclinical Testing Center, Level Biotechnology Inc., Taiwan

May 2018 – Dec. 2021

- Responsible for the contract research organizations (CRO) preclinical testing center under the GLP regulation (FDA GLP compliant, OECD GLP, and Taiwan-FDA GLP)
- Serving as chairman of IACUC and Responsible for managing the animal facility center under the AAALAC Guide.
- Serving as the biosafety officer to oversee biosafety-related issues within the establishment.

Director of Preclinical Development, APRINOIA Therapeutics Inc., Taiwan

Sep. 2016 – Feb. 2018

- Develop the in-house in vivo study of neurodegeneration disease animal models (Alzheimer's disease and Parkinson disease) for drug efficacy evaluation.
- Design the preclinical toxicology study of IND package for drug safety evaluation (tau PET tracer).

Testing Manager, Animal Laboratory for Biomedical Research (AAALAC International Accreditation, ISO/IEC 17025), Industrial Technology Research Institute. Hsinchu, Taiwan,

Jul. 2014 – Aug. 2016

- Responsible for maintenance of the animal facility under the IACUC/AAALAC guides and the toxicity testing for safety testing by ISO17025 certification.
- Established the alternative *in vitro* toxicity tests for cosmetic and chemical safety evaluation. Including Skin Irritation/Corrosion Test(OECD 431 & 439), Skin Sensitization Test, and 3T3 NRU Phototoxicity Test (OECD 432), Bacterial reverse gene mutation assay (OECD471)
- Developed the Novel in vitro Skin Sensitization Test. (Patent: TW: I493036; JP 2014-257422)

Senior Researcher and Manager, Pharmacodynamics Technology Department, Biomedical Engineering Research Laboratories, Industrial Technology Research Institute. Hsinchu, Taiwan

Jan 2008 – Aug 2016

- Designed the GLP toxicological study (IND package)for drug candidates. Including, one NCE project (FLT3 inhibitor), two nanoparticles (SN38-PM, Iron Oxide nanoparticle), and botanic drug (psoriasis project)
- Established and designed the pharmacological and non-GLP toxicological study for drug candidates. Including, two NCE projects (FLT3 inhibitor, dual Aurora B/FLT3 inhibitor), three nanoparticle projects (SN38-PM, Iron Oxide nanoparticle and hyperthermia-mediated drug delivery drug), two botanic drug candidates (psoriasis project, anti-hepatocellular carcinoma project, and neural protection project), and two ADC project (anti-Her2 ADC and anti-EGFR ADC)
- Functional Food Projects: *Antrodia camphorata* and *Ganoderma lucidum* for immune-modulating activity. *Chlorella* for anti-diabetic activity. Toxicity assay of *Vernonia amygdalina* (28 days repeated-dose general toxicology and Genetic toxicity)

Awards and Honors:

- DABT, Diplomate, American Board of Toxicology, 2022-present
- DASTA, Diplomate of the Toxicology Society of Taiwan (台毒(王)證字第 05 號), 2024-present
- Testing Laboratory Manager Training, ISO/IEC 17025 /TAF17025, (TAF-QM101007-C-23)
- Pharmacist Licenses of R.O.C. (藥字第 022449 號)

Selected Publications:

Refereed Publications (21 SCI Papers)

1. Yeh TT, Ho MY, Chen WY, Hsu YC, Ku WC, **Tseng HW**, Chen ST, Chen SF. Comparison of different fractionation strategies for in-depth phosphoproteomics by liquid chromatography tandem mass spectrometry. *Anal Bioanal Chem*. 2019 Apr 22.
2. Ke LY, Kuo ZK, Chen YS, Yeh TY, Dong M, **Tseng HW**, Liu CH. Cancer immunotherapy μ -environment LabChip: taking advantage of optoelectronic tweezers. *Lab Chip*. 2017 Dec 19;18(1):106-114.
3. Liu L, Ye Q, Lu M, Chen ST, **Tseng HW**, Lo YC, Ho C. A New Approach to Deliver Anti-cancer Nanodrugs with Reduced Off-target Toxicities and Improved Efficiency by Temporarily Blunting the Reticuloendothelial System with Intralipid. *Sci Rep*. 2017 Nov 23;7(1):16106.
4. Teng HW, Hung MH, Chen LJ, Chang MJ, Hsieh FS, Tsai MH, Huang JW, Lin CL, **Tseng HW**, Kuo ZK, Jiang JK, Yang SH, Shiau CW, Chen KF. Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma. *Sci Rep*. 2016 Oct 18;6:35308.
5. Kuo ZK, Lai PL, Toh EK, Weng CH, **Tseng HW**, Chang PZ, Chen CC, Cheng CM. Osteogenic differentiation of preosteoblasts on a hemostatic gelatin sponge. *Sci Rep*. 2016 Sep 12;6:32884.
6. Kuo ZK, Lin MW, Lu IH, Yao HJ, Wu HC, Wang CC, Lin SH, Wu SY, Tong TS, Cheng YC, Yen JH, Ko CH, Chiou SJ, Pan IH, **Tseng HW**. Antiangiogenic and antihepatocellular carcinoma activities of the *Juniperus chinensis* extract. *BMC Complement Altern Med*. 2016 Aug 8;16:277.
7. Jagtap AD, Chang PT, Liu JR, Wang HC, Kondekar NB, Shen LJ, **Tseng HW**, Chen GS, Chern JW. (2014) Novel acylureidoinolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia. *Eur J Med Chem*. 2014 Oct 6;85:268-88
8. Wang HC, Jagtap AD, Chang PT, Liu JR, Liu CP, **Tseng HW**, Chen GS, Chern JW. (2014) Bioisosteric replacement of an acylureido moiety attached to an indolin-2-one scaffold with a malonamido or a 2/4-pyridinoylamido moiety produces a selectively potent Aurora-B inhibitor. *Eur J Med Chem*. 2014 Sep 12;84:312-34.
9. Chen KJ, Chaung EY, Wey SP, Lin KJ, Cheng F, Lin CC, Liu HL, **Tseng HW**, Liu CP, Wei MC, Liu CM, Sung HW. (2014) Hyperthermia-Mediated Local Drug Delivery by a Bubble-Generating Liposomal System for Tumor-Specific Chemotherapy. *ACS Nano*. 2014 Apr 21. (SCI IF2011=9.855)
10. Ko CH, Cheng CF, Lai CP, Tzu TH, Chiu CW, Lin MW, Wu SY, Sun CY, **Tseng HW**, Wang CC, Kuo ZK, Wang LM, Chen SF. (2013) Differential proteomic analysis of cancer stem cell properties in hepatocellular carcinomas by isobaric tag labeling and mass spectrometry. *J Proteome Res*. 12(8):3573-85 (SCI IF2011=5.46)
11. Cheng CF, Lu IH, **Tseng HW**, Sun CY, Lin LT, Kuo ZK, Pan IH, Ko CH. (2013) Anti-tumor effect of Periplocin in TRAIL-resistant human hepatocellular carcinoma cells through down-regulation of IAPs. *Evid Based Complement Alternat Med*(SCI IF₂₀₁₁=2.964)
12. Lee LT, Tsai HP, Wang CC, Chang CN, Liu WC, Hsu HC, Hsieh CT, Chen YC, H **Tseng HW**, Gaua RJ, Liu SH, Chen IS, Iinuma M. (2012) Guttiferone F from the fruit of *Garcinia multiflora* and its anti-hepatocellular carcinoma activity. *Biomedicine & Preventive Nutrition*. 3(3):247-252
13. Lin YP, Chen TY, **Tseng HW**, Lee MH, Chen ST. (2012) Chemical and biological evaluation of nephrocizin in protecting nerve growth factor-differentiated PC12 cells by 6-hydroxydopamine-induced neurotoxicity. *Phytochemistry*. 2012; 84:102-15 (SCI IF₂₀₁₁=3.150)

